INAMED CORP
NT 10-Q, 1997-08-14
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Previous: COMMERCE GROUP CORP /WI/, 10-Q, 1997-08-14
Next: SEAL HOLDINGS CORP, 10QSB, 1997-08-14



                             UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                        WASHINGTON, D.C.  20549




                              FORM 12B-25
                       NOTIFICATION OF LATE FILING

                             (Check one):

[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR

For Period Ended: June 30, 1997

[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR

For the Transition Period Ended:

Read Attached Instruction Sheet Before Preparing Form.  Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, 
identify the Item(s) to which the notification relates: not applicable

Part I - Registrant Information

Full Name of Registrant

INAMED CORPORATION

Address of Principal Executive Office:

3800 Howard Hughes Parkway, Suite #900
Las Vegas, Nevada  89109

Part II - Rules 12b-25  (b) and (c)

If the subject report could not be filed without unreasonable effort or 
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed.  (Check box if appropriate)

[X]        (a) The reasons described in reasonable detail in Part III of this
               form could not be eliminated without unreasonable effort or 
               expense;

[ ]        (b) The subject annual report, semi-annual report, transition report
               on Form 10-K, Form 20-F, 11-K or From N-SAR, or portion thereof
               will be filed on or before the fifteenth calendar day following 
               the prescribed due date; or the subject quarterly report or
               transition report on Form 10-Q, or portion thereof will be 
               filed on or before the fifth calendar day following the 
               prescribed due date; and 
                                                                                
[ ]        (c) The accountant's statement or other exhibit required by Rule 
               12b-25 (c) has been attached if applicable
                                                                               
Part III - Narrative

State below in reasonable detail the reason why Form 10-K, 20-F, 11-K, 10-Q,
N-SAR or the transition report or portion thereof could not be filed within
the prescribed time period.

As previously disclosed in press releases dated April 1, April 15, May 8 and
May 15, 1997, the Company was unable to timely file its annual report on Form
10-K for calendar/fiscal year 1996.  Because the Form 10-K has not yet been
completed, the Form 10-Q for the second quarter of 1997 could not be filed
within its prescribed time period without unreasonable effort or expense. 
The Company expects to file Form 10-Q concurrently with the Form 10-K, which
it anticipates filing before August 22, 1997.

Part IV - Other Information

(1) Name and telephone number of person to contact in regard to this
notification

Donald K. McGhan, Chairman of the Board and Chief Executive Officer
INAMED Corporation  (702) 791-3388

(2) Have all other periodic reports required under section 13 or 15 (d)
of the Securities Exchange Act of 1934 or section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter 
periods that the registrant was required to file such report(s) been filed?
If the answer is no, identify report(s).
                                  [ ] Yes     [X] NO

Form 10-K for the period ended December 31, 1996
Form 10-Q for the period ended March 31, 1997

(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by
the earning statements to be included in the subject report or portion thereof?
                                  [ ] Yes     [X] NO

If so: attach an explanation of the anticipated change, both narratively and 
quantitatively, and if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.


                            INAMED CORPORATION

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date: August 14, 1997                   By          /S/ DONALD K. MCGHAN
                                         Chairman of the Board and CEO






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission